Amgen Takes Almost 40% Of US Bevacizumab Market
As Company Launches Biosimilar Infliximab In US
Executive Summary
Amgen’s biosimilar revenues were more than $350m in the second quarter of this year, as the company benefitted from the ‘innovator product’ commercialization model across its increasingly broad portfolio of biosimilars.